Fiche centre
University of Colorado
Aurora — United States
Essais liés17clinical trials
VilleAuroralocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05639114
Essais cliniques associés
17| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Irreversible Electroporation | Cancer | Non applicable | NCT04972097 | PRESERVE — Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue | COMPLETED |
| ZL-1310 | Cancer | Phase 3 | NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | RECRUITING |
| adaptive DBS (aDBS) | Parkinson | Non applicable | NCT07808346 | Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease | ACTIVE_NOT_RECRUITING |
| CAVS-MS — Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis | SEP | À vérifier | NCT04495556 | CAVS-MS — Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 1 | NCT03972306 | A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis | COMPLETED |
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| Ianalumab | Lupus | Phase 3 | NCT05639114 | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | ACTIVE_NOT_RECRUITING |
| RE104 for Injection | Sclérose latérale amyotrophique | Phase 2 | NCT07002034 | RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | RECRUITING |
| CABA-201 | Myasthénie | Phase 1/2 | NCT06359041 | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | RECRUITING |
| Inebilizumab | Lupus | Phase 2 | NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | RECRUITING |
| Hybrid argon plasma ablation (HAPC) | Cancer | Non applicable | NCT03621319 | BURN — Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique | TERMINATED |
| BIA 28-6156 | Parkinson | À vérifier | NCT07522606 | Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study | NO_LONGER_AVAILABLE |
| Deep Brain Stimulation (DBS) | Parkinson | À vérifier | NCT02071134 | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | RECRUITING |
| Flow Detection System | Migraine | Phase 3 | NCT01773252 | PFO Detection — Right to Left Cardiac Shunt Detection | TERMINATED |
| Pegcetacoplan (APL-2) | Sclérose latérale amyotrophique | Phase 2 | NCT04579666 | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | TERMINATED |
| 3, 4-Diaminopyridine | Myasthénie | À vérifier | NCT01825395 | Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome | APPROVED_FOR_MARKETING |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |